Oban BioPharma

Oban BioPharma is a Seattle-based biotechnology company pioneering the development of in vivo cell therapies for cancer and other serious diseases. By leveraging advanced gene delivery technologies, the company aims to engineer therapeutic immune cells directly within the patient's body, bypassing the complexities and costs of traditional ex vivo manufacturing. Oban's platform is designed to create highly potent and durable CAR-T and NK cell responses through precise genetic modification. The company was founded by leading experts in hematology and gene therapy from the Fred Hutchinson Cancer Center, including Dr. Hans-Peter Kiem. Currently in the pre-clinical stage, Oban is building a pipeline of candidates focused on oncology and hematological malignancies. The company is backed by prominent life science investors, including ARCH Venture Partners.